StreetInsider.com News Articles

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

Wed, 27 May 2026 16:05:00 -0400

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June:

2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m. ET
Goldman Sachs 47^th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

Wed, 27 May 2026 16:05:00 -0400

2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m. ET
Goldman Sachs 47^th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

Wed, 27 May 2026 16:05:00 -0400

2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m. ET
Goldman Sachs 47^th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

Wed, 27 May 2026 16:05:00 -0400

2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m. ET
Goldman Sachs 47^th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in

Relay Therapeutics (RLAY) PT Raised to $28 at H.C. Wainwright

Tue, 26 May 2026 06:51:45 -0400

(Updated - May 26, 2026 6:51 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Relay Therapeutics (NASDAQ: RLAY) to $28.00 (from $25.00) while maintaining a Buy rating.

The analyst commented: "At the 2026 International Society for the Study of Vascular Anomalies World Congress in Philadelphia, Relay presented initial results from the Part 1 dose randomization portion of the ongoing Phase 2 ReInspire trial evaluating zovegalisib in adults and adolescents with PIK3CA-driven vascular anomalies; Across the three dose cohorts (i.e., 100mg BID [n=11; 1 median prior Rx; 73% prior alpelisib/sirolimus; 73% PROS, 27% LM], 300mg BID [n=11; 2 median

Relay Therapeutics (RLAY) PT Raised to $28 at H.C. Wainwright

Tue, 26 May 2026 06:51:45 -0400

(Updated - May 26, 2026 6:51 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Relay Therapeutics (NASDAQ: RLAY) to $28.00 (from $25.00) while maintaining a Buy rating.

Relay Therapeutics (RLAY) PT Raised to $26 at Guggenheim

Tue, 26 May 2026 06:44:34 -0400

(Updated - May 26, 2026 6:44 AM EDT)

Guggenheim analyst Brad Canino raised the price target on Relay Therapeutics (NASDAQ: RLAY) to $26.00 (from $22.00) while maintaining a Buy rating.

The analyst commented: "KOL commentary from ISSVA suggests RLAY's zovegalisib is a meaningful improvement over alpelisib (Vijoice, NVS) that is unlikely to leave room for additional efficacy. The safety profile is amenable for long-term dosing, but the low-grade hyperglycemia is an open question to address. As such, there is interest in the middle zovegalisib 200mg BID dose (i.e., 400mg QD) and potential induction/ maintenance strategies. The lymphatic malformations (LM) subgroup commercial opportunity

Relay Therapeutics (RLAY) PT Raised to $26 at Guggenheim

Tue, 26 May 2026 06:44:34 -0400

(Updated - May 26, 2026 6:44 AM EDT)

Guggenheim analyst Brad Canino raised the price target on Relay Therapeutics (NASDAQ: RLAY) to $26.00 (from $22.00) while maintaining a Buy rating.

Form 8-K Relay Therapeutics, Inc. For: May 20

Thu, 21 May 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260521/26536743.html

Form 8-K Relay Therapeutics, Inc. For: May 20

Thu, 21 May 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260521/26536743.html

Form 424B5 Relay Therapeutics, Inc.

Thu, 21 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260521/26535428.html

Form 424B5 Relay Therapeutics, Inc.

Thu, 21 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260521/26535428.html

Relay Therapeutics prices $275 million public stock offering at $12 per share

Wed, 20 May 2026 20:21:38 -0400

Relay Therapeutics Inc. (NASDAQ: RLAY) announced the pricing of a public offering of 22,916,667 shares of common stock at $12.00 per share. The Cambridge, Massachusetts-based clinical-stage precision medicine company expects gross proceeds of approximately $275 million before underwriting discounts and expenses.